Guangzhou Bio-gene Technology Co., Ltd
Clinical trials sponsored by Guangzhou Bio-gene Technology Co., Ltd, explained in plain language.
-
New Dual-Target CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for adults aged 18-85 whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check safety, find the r…
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 08:19 UTC
-
New immune cell therapy targets tough blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new treatment called BAFFR CAR-T for people with B-cell tumors that have come back or not responded to other therapies. The study will enroll 12 adults aged 18-85 to check the therapy's safety and find the right dose. The approach uses a patient's o…
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New CAR-T therapy targets Hard-to-Treat blood cancer
Disease control Not yet recruitingThis early study tests a new type of CAR-T cell therapy (BCMA-GPRC5D) in 10 adults with relapsed/refractory multiple myeloma who have already tried at least three prior treatments. The therapy uses the patient's own immune cells, modified to attack two cancer targets, and is give…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 13, 2026 16:03 UTC